UBS Group Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $288.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective boosted by equities research analysts at UBS Group from $253.00 to $288.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s price objective points to a potential upside of 18.37% from the company’s current price.

A number of other brokerages also recently issued reports on ALNY. Wells Fargo & Company lifted their price objective on shares of Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Morgan Stanley boosted their target price on shares of Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Tuesday. SVB Leerink boosted their target price on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a research report on Tuesday. Needham & Company LLC boosted their target price on shares of Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Barclays boosted their target price on shares of Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the stock an “overweight” rating in a research report on Tuesday. Eight equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $247.09.

Alnylam Pharmaceuticals Stock Down 1.5 %

Shares of Alnylam Pharmaceuticals stock traded down $3.70 on Friday, reaching $243.30. The stock had a trading volume of 138,172 shares, compared to its average volume of 852,787. The company has a 50 day moving average price of $157.89 and a 200 day moving average price of $164.23. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $252.87. The stock has a market capitalization of $30.78 billion, a P/E ratio of -90.78 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to analysts’ expectations of $428.01 million. During the same period in the previous year, the firm earned ($1.40) EPS. The firm’s quarterly revenue was up 54.8% on a year-over-year basis. On average, analysts forecast that Alnylam Pharmaceuticals will post -3.75 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 1,605 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total transaction of $370,755.00. Following the completion of the transaction, the chief financial officer now directly owns 28,892 shares in the company, valued at $6,674,052. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 1,605 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $231.00, for a total transaction of $370,755.00. Following the completion of the transaction, the chief financial officer now directly owns 28,892 shares in the company, valued at $6,674,052. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the transaction, the director now owns 8,436 shares of the company’s stock, valued at $1,253,589.60. The disclosure for this sale can be found here. Insiders sold a total of 67,357 shares of company stock worth $13,436,711 in the last three months. Company insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ALNY. Teachers Retirement System of The State of Kentucky grew its holdings in shares of Alnylam Pharmaceuticals by 8.1% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 33,213 shares of the biopharmaceutical company’s stock worth $4,964,000 after buying an additional 2,500 shares in the last quarter. Cetera Advisors LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $238,000. Burney Co. grew its holdings in shares of Alnylam Pharmaceuticals by 371.9% during the first quarter. Burney Co. now owns 27,059 shares of the biopharmaceutical company’s stock worth $4,044,000 after buying an additional 21,325 shares in the last quarter. Swedbank AB purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $3,084,000. Finally, Plato Investment Management Ltd grew its holdings in shares of Alnylam Pharmaceuticals by 2,666.3% during the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock worth $674,000 after buying an additional 4,346 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.